These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 26039570)

  • 1. Design, Synthesis, and Structure-Activity Relationships of Pyridine-Based Rho Kinase (ROCK) Inhibitors.
    Green J; Cao J; Bandarage UK; Gao H; Court J; Marhefka C; Jacobs M; Taslimi P; Newsome D; Nakayama T; Shah S; Rodems S
    J Med Chem; 2015 Jun; 58(12):5028-37. PubMed ID: 26039570
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 2,3,5-Trisubstituted pyridines as selective AKT inhibitors-Part I: Substitution at 2-position of the core pyridine for ROCK1 selectivity.
    Lin H; Yamashita DS; Zeng J; Xie R; Wang W; Nidarmarthy S; Luengo JI; Rhodes N; Knick VB; Choudhry AE; Lai Z; Minthorn EA; Strum SL; Wood ER; Elkins PA; Concha NO; Heerding DA
    Bioorg Med Chem Lett; 2010 Jan; 20(2):673-8. PubMed ID: 20006497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of 5H-chromeno[3,4-c]pyridine and 6H-isochromeno[3,4-c]pyridine derivatives as potent and selective dual ROCK inhibitors.
    Hu Z; Wang C; Sitkoff D; Cheadle NL; Xu S; Muckelbauer JK; Adam LP; Wexler RR; Quan ML
    Bioorg Med Chem Lett; 2020 Nov; 30(21):127474. PubMed ID: 32805407
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A review on ROCK-II inhibitors: From molecular modelling to synthesis.
    Shah S; Savjani J
    Bioorg Med Chem Lett; 2016 May; 26(10):2383-2391. PubMed ID: 27080184
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ROCK inhibitors 3: Design, synthesis and structure-activity relationships of 7-azaindole-based Rho kinase (ROCK) inhibitors.
    Bandarage UK; Cao J; Come JH; Court JJ; Gao H; Jacobs MD; Marhefka C; Nanthakumar S; Green J
    Bioorg Med Chem Lett; 2018 Aug; 28(15):2622-2626. PubMed ID: 30082069
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis, and biological evaluation of novel, highly active soft ROCK inhibitors.
    Boland S; Bourin A; Alen J; Geraets J; Schroeders P; Castermans K; Kindt N; Boumans N; Panitti L; Fransen S; Vanormelingen J; Stassen JM; Leysen D; Defert O
    J Med Chem; 2015 May; 58(10):4309-24. PubMed ID: 25898023
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and biological evaluation of urea derivatives as highly potent and selective rho kinase inhibitors.
    Yin Y; Lin L; Ruiz C; Khan S; Cameron MD; Grant W; Pocas J; Eid N; Park H; Schröter T; Lograsso PV; Feng Y
    J Med Chem; 2013 May; 56(9):3568-81. PubMed ID: 23570561
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis, and biological evaluation of urea-based ROCK2 inhibitors.
    Wang L; Qi J; Fan M; Yao L
    Chem Biol Drug Des; 2021 Dec; 98(6):969-978. PubMed ID: 34581498
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and biological evaluation of 4-quinazolinones as Rho kinase inhibitors.
    Fang X; Chen YT; Sessions EH; Chowdhury S; Vojkovsky T; Yin Y; Pocas JR; Grant W; Schröter T; Lin L; Ruiz C; Cameron MD; LoGrasso P; Bannister TD; Feng Y
    Bioorg Med Chem Lett; 2011 Mar; 21(6):1844-8. PubMed ID: 21349713
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ROCK inhibitors 4: Structure-activity relationship studies of 7-azaindole-based rho kinase (ROCK) inhibitors.
    Bandarage UK; Court J; Gao H; Nanthakumar S; Come JH; Giroux S; Green J
    Bioorg Med Chem Lett; 2021 Feb; 33():127721. PubMed ID: 33259926
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of Selective Dual ROCK1 and ROCK2 Inhibitors Using Structure-Based Drug Design.
    Hobson AD; Judge RA; Aguirre AL; Brown BS; Cui Y; Ding P; Dominguez E; DiGiammarino E; Egan DA; Freiberg GM; Gopalakrishnan SM; Harris CM; Honore MP; Kage KL; Kapecki NJ; Ling C; Ma J; Mack H; Mamo M; Maurus S; McRae B; Moore NS; Mueller BK; Mueller R; Namovic MT; Patel K; Pratt SD; Putman CB; Queeney KL; Sarris KK; Schaffter LM; Stoll V; Vasudevan A; Wang L; Wang L; Wirthl W; Yach K
    J Med Chem; 2018 Dec; 61(24):11074-11100. PubMed ID: 30384606
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of potent and selective urea-based ROCK inhibitors: Exploring the inhibitor's potency and ROCK2/PKA selectivity by 3D-QSAR, molecular docking and molecular dynamics simulations.
    Mei D; Yin Y; Wu F; Cui J; Zhou H; Sun G; Jiang Y; Feng Y
    Bioorg Med Chem; 2015 May; 23(10):2505-17. PubMed ID: 25882521
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of Novel ROCK1 Inhibitors via Integrated Virtual Screening Strategy and Bioassays.
    Shen M; Tian S; Pan P; Sun H; Li D; Li Y; Zhou H; Li C; Lee SM; Hou T
    Sci Rep; 2015 Nov; 5():16749. PubMed ID: 26568382
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rho Kinase (ROCK) Inhibitors and Their Therapeutic Potential.
    Feng Y; LoGrasso PV; Defert O; Li R
    J Med Chem; 2016 Mar; 59(6):2269-300. PubMed ID: 26486225
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo optimization of 2,3-diaminopyrazine Rho Kinase inhibitors for the treatment of glaucoma.
    Chen HH; Namil A; Severns B; Ward J; Kelly C; Drace C; McLaughlin MA; Yacoub S; Li B; Patil R; Sharif N; Hellberg MR; Rusinko A; Pang IH; Combrink KD
    Bioorg Med Chem Lett; 2014 Apr; 24(8):1875-9. PubMed ID: 24684843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis and biological characterization of selective LIMK inhibitors.
    Boland S; Bourin A; Alen J; Geraets J; Schroeders P; Castermans K; Kindt N; Boumans N; Panitti L; Vanormelingen J; Fransen S; Van de Velde S; Defert O
    Bioorg Med Chem Lett; 2015 Sep; 25(18):4005-10. PubMed ID: 26233434
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of Rho-kinase inhibitors by docking-based virtual screening.
    Shen M; Yu H; Li Y; Li P; Pan P; Zhou S; Zhang L; Li S; Lee SM; Hou T
    Mol Biosyst; 2013 Jun; 9(6):1511-21. PubMed ID: 23549429
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of a novel ROCK2 inhibitor with anti-migration effects via docking and high-content drug screening.
    Chong CM; Kou MT; Pan P; Zhou H; Ai N; Li C; Zhong HJ; Leung CH; Hou T; Lee SM
    Mol Biosyst; 2016 Aug; 12(9):2713-21. PubMed ID: 27354305
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel ROCK inhibitors for the treatment of pulmonary arterial hypertension.
    Shaw D; Hollingworth G; Soldermann N; Sprague E; Schuler W; Vangrevelinghe E; Duggan N; Thomas M; Kosaka T; Waters N; van Eis MJ
    Bioorg Med Chem Lett; 2014 Oct; 24(20):4812-7. PubMed ID: 25248678
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances in the development of Rho-associated protein kinase (ROCK) inhibitors.
    Pan P; Shen M; Yu H; Li Y; Li D; Hou T
    Drug Discov Today; 2013 Dec; 18(23-24):1323-33. PubMed ID: 24076262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.